Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Discovery of Biomarkers to Predict Response to Checkpoint Blockade in Ovarian Cancer
FY 2016-17
Summary
There are an approximately 2 800 new cases of ovarian cancer in Canada each year; while an estimated 1 700 Canadian women will die from ovarian cancer this year. Current treatments for advanced ovarian cancer rely on surgery and chemotherapy, but have poor long term effects due to resistance to chemotherapy. This highlights a serious unmet medical need in advanced ovarian cancer patients.One promising approach for treating advanced ovarian cancer uses the body's immune system that normally fights off the flu and bacterial infections. It has been shown that the immune system can also recognize and fight off cancer cells. However, cancer cells can also hide from and turn off the immune response. Cancer immunotherapy uses medicines that activate the immune system so it can continue fighting cancer. One type of cancer immunotherapy targets the natural brakes or checkpoints in the body that normally stops the immune system from overreacting and attacking the body. By using drugs called checkpoint inhibitors, we can bypass this checkpoint, allowing the immune system to find and kill cancer cells. Several checkpoint inhibitors have shown success in the clinic, however, there are major gaps in understanding how to improve this drug so more patients will benefit from this therapy.The goal of the project is to find special characteristics of the patient's immune system that allows for a successful response to checkpoint inhibitors. We will study the effects of a checkpoint inhibitor (pembrolizumab) in advanced ovarian cancer patients and look at changes in their immune system. In this way, we can predict which patients would benefit from treatment with these types of drugs, enabling us to tailor medical decisions and treatments to patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367212
Name
Lien Scott
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovery of Biomarkers to Predict Response to Checkpoint Blockade in Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cancer Immunotherapy; Checkpoint Blockade; Ovarian Cancer; Programmed Cell Death 1
Abstract
There are an approximately 2 800 new cases of ovarian cancer in Canada each year; while an estimated 1 700 Canadian women will die from ovarian cancer this year. Current treatments for advanced ovarian cancer rely on surgery and chemotherapy, but have poor long term effects due to resistance to chemotherapy. This highlights a serious unmet medical need in advanced ovarian cancer patients.One promising approach for treating advanced ovarian cancer uses the body's immune system that normally fights off the flu and bacterial infections. It has been shown that the immune system can also recognize and fight off cancer cells. However, cancer cells can also hide from and turn off the immune response. Cancer immunotherapy uses medicines that activate the immune system so it can continue fighting cancer. One type of cancer immunotherapy targets the natural brakes or checkpoints in the body that normally stops the immune system from overreacting and attacking the body. By using drugs called checkpoint inhibitors, we can bypass this checkpoint, allowing the immune system to find and kill cancer cells. Several checkpoint inhibitors have shown success in the clinic, however, there are major gaps in understanding how to improve this drug so more patients will benefit from this therapy.The goal of the project is to find special characteristics of the patient's immune system that allows for a successful response to checkpoint inhibitors. We will study the effects of a checkpoint inhibitor (pembrolizumab) in advanced ovarian cancer patients and look at changes in their immune system. In this way, we can predict which patients would benefit from treatment with these types of drugs, enabling us to tailor medical decisions and treatments to patients.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lien, Scott
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~